Table 1 Tumor characteristics and treatment outcomes
Patient | Age (Sex) | Tumor size (cm) | TNM stage | Tumor histology | ARMS-PCR | Tumor puritya | Treatment | Disease outcomec (months) | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1° | 2° | 1° | 2° | 1° | 2° | 1° | 2° | 1° | 2° | ||||
P1 | 50 (F) | 1.8 × 2.0 | 1.6 × 1.7 | cT3N2M1b IVa | AD | MAD | E19 del | NT | 55% | 51% | Gefitinib + RT | Progressive (8) | Progressive (8) |
P2 | 70 (M) | 2.3 × 1.7 | 3.3 × 2.5 | cT4N0M1b IVa | AD | MAD | E19 del | NT | 31% | 20% | Gefitinib + RT | Stable (18) | Stable (18) |
P3 | 54 (M) | 2.3 × 1.7 | 3.0 × 2.0 | cT1N2M1b IVa | AD | MAD | E19 del | NT | 50% | 45% | Gefitinib + RT | Stable (10) | Progressive (10) |
P4 | 54 (F) | 3.4 × 3.0 | 5.3 × 3.1 | cT2N3M1b IVb | AD | MAD | E19 del | NT | 37% | 35% | Gefitinib + RT | Progressive (14) | Progressive (14) |
P5 | 73 (F) | 2.6 × 1.7 | 4.3 × 2.8 | cT2N0M1c IVb | AD | MAD | E19 del | NT | 52% | 52% | Gefitinib + RT | Progressive (18) | Stable (18) |
P6 | 67 (M) | 4.4 × 2.8 | 2.5 × 1.8 | cT2N2M1b IVa | AD | MAD | E19 del | NT | 26% | 32% | Gefitinib + RT | Stable (5) | Stable (5) |
P7 | 64 (F) | 2.7 × 2.1 | 2.1 × 1.8 | cT2N2M1b IVa | P-NSCC | MAD | L858R | NT | 24% | 37% | Gefitinib | Deceased (7) | Deceased (7) |
P8 | 54 (F) | 2.8 × 2.4 | 1.5 × 0.9 | cT1N1M1b IVa | AD | MAD | L858R | NT | 31% | 34% | Gefitinib + CT + RT | Progressive (3) | Stable (3) |
P9 | 61 (F) | 3.2 × 2.8 | 2.5 × 2.4 | cT2N3M1c IVb | AD | MAD | L858R | NT | 60% | 57% | Erlotinib + CT | Progressive (7) | Stable (7) |
P10 | 50 (M) | 1.7 × 0.6 | 1.9 × 1.7 | cT1bN0M1c IVb | AD | MAD | – | L858R | 24% | 25% | Osimertinib | Stable (4) | Stable (4) |
P11 | 66 (M) | 1.5 × 1.3 | 2.6 × 1.3 | cT1bN2M1c IVb | AD | MAD | – | L858R | 94% | 30% | Gefitinib | Progressive (17) | Stable (17) |
P12 | 49 (M) | 2.6 × 1.5 | 3.6 × 1.1 | cT3N0M1c IVb | AD | MAD | G719Xb | NT | 47% | 51% | Osimertinib + RT | Progressive (12) | Stable (12)) |
P13 | 59 (M) | 5.6 × 6.3 | 1.2 × 1.4 | cT3N0M1c IVb | AD | MAD | L861Q | NT | 67% | 79% | Gefitinib | Deceased (14) | Deceased (14) |
P14 | 52 (M) | 2.0 × 1.7 | 2.5 × 2.7 | cT1N2M1b IVa | AD | MAD | EML4-ALK | NT | 70% | 33% | Crizotinib + RT | Stable (13) | Stable (13) |
P15 | 63 (M) | 3.4 × 3.7 | 7.4 × 7.9 | cT2N2M1c IVb | AD | MAD | – | NT | 47% | 49% | CT | Progressive (5) | Progressive (5) |
P16 | 53 (F) | 4.2 × 7.4 | 2.1 × 2.3 | cT4N0M1a IVb | AD | MAD | – | NT | 35% | 35% | CT + RT | Stable (3) | Stable (3) |
P17 | 53 (M) | 3.2 × 1.9 | 4.4 × 1.8 | cT2N2M1b IVa | AD | MAD | – | NT | 33% | 74% | CT + RT | Deceased (2) | Deceased (2) |